PharmaSGP Holding SE Revises 2025 Revenue Forecast

On July 11, 2025, PharmaSGP Holding SE announced a revision of its revenue forecast for the fiscal year 2025. The Management Board now anticipates consolidated revenues to be between €132.0 million and €138.0 million, an adjustment from the previous range of €122.0 million to €128.0 million.

The expected adjusted EBITDA remains between €37.0 million and €39.0 million, resulting in an adjusted EBITDA margin of 26.8% to 29.5%. The previous forecast estimated a margin of 28.9% to 32.0%.

This revision considers ongoing uncertainties in the geopolitical and economic landscape. The situation's impact on Germany and Europe is still challenging to predict. PharmaSGP plans to release preliminary figures for the first half of 2025 on September 11, followed by a detailed half-year report on September 25.